1. Anwendungsbeobachtung: Transparenz herstellen, Missbrauch abstellen [Non-interventional studies: Create transparency, stop misuse] (2009) German Federal Ministry of Health. http://www.bmg.bund.de/fileadmin/redaktion/pdf_pressemeldungen/2009/091002-PM-anwendungsbeobachtung.pdf (latest access: 16 AUG 2012) Press Release
2. Lassila R, Rothschild C, De Moerloose P, Richards M, Perez R, Gajek H (2005) Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. Haemophilia 11(4):353–359. doi: 10.1111/j.1365-2516.2005.01114.x
3. Blanchette VS, Shapiro AD, Liesner RJ, Hernandez Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM (2008) Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 6(8):1319–1326. doi: 10.1111/j.1538-7836.2008.03032.x
4. Ewenstein BM, Collins P, Tarantino MD, Negrier C, Blanchette V, Shapiro AD, Baker D, Spotts G, Sensel M, Yi SE, Gomperts ED (2004) Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12–18, 2003, Birmingham, UK. Semin Hematol 41(1 Suppl 2):1–16
5. Negrier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A, Schroth P, Ewenstein B (2008) Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost 100(2):217–223